drugset / Trial / NCT01127087
Oxazyme in Patients With Hyperoxaluria
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and hence oxalate excretion in the urine.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-09
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxazyme | Protein / enzyme biologic | 1 g | Oral |
Indications
No indication recorded.